

APR 4 - 2007

Summary of Safety and Effectiveness

Date: January 23, 2007

Manufacturer:

Encore Medical, L.P.
9800 Metric Blvd
Austin, TX 78758

Trade Name: FMP™ Metal/Metal
Acetabular Insert

Common Name: Acetabular Insert

Contact Person:

Teffany Hutto
Regulatory Affairs Specialist
Phone: (512) 834-6255
Fax: (512) 834-6313
Email: Teffany_Hutto@encoremed.com

Classification Name: Hip joint metal/metal
semi-constrained, with an uncemented
component, prosthesis per 21 CFR 888.3330

Description: The modification consists of a change to the Instructions for Use to minimize the necessity for multiple IFU's and to update the contents to reflect current practice.

Intended Use: Joint replacement is indicated for patients suffering from disability due to:

- noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis of the natural femoral head;
- rheumatoid arthritis;
- correction of functional deformity;
- femoral fracture;

This device may also be indicated in the salvage of previously failed surgical attempts.

Comparable Features to Predicate Device(s): Features comparable to predicate devices include the same materials, design, indications, packaging, and sterilization.

Summary of Safety and Effectiveness

Date: January 23, 2007

Manufacturer:

Encore Medical, L.P.
9800 Metric Blvd
Austin, TX 78758

Trade Name: Metal/Metal Hip System

Common Name: Total Hip Prosthesis, Semi-Constrained

Contact Person:

Teffany Hutto
Regulatory Affairs Specialist
Phone: (512) 834-6255
Fax: (512) 834-6313
Email: Teffany_Hutto@encoremed.com

Classification Name: Hip joint metal/metal semi-constrained, with an uncemented component, prosthesis per 21 CFR 888.3330

Description: The modification consists of a change to the Instructions for Use to minimize the necessity for multiple IFU's and to update the contents to reflect current practice.

Intended Use: Joint replacement is indicated for patients suffering from disability due to:

- noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis of the natural femoral head;
- rheumatoid arthritis;
- correction of functional deformity;
- femoral fracture;

This device may also be indicated in the salvage of previously failed surgical attempts.

Comparable Features to Predicate Device(s): Features comparable to predicate devices include the same materials, design, indications, packaging, and sterilization.

Summary of Safety and Effectiveness

Date: January 23, 2007

Manufacturer:
Encore Medical, L.P.
9800 Metric Blvd
Austin, TX 78758

Trade Name: CLP® Offset Total Hip System

Common Name: Total Hip Prosthesis, Semi-Constrained

Contact Person:
Teffany Hutto
Regulatory Affairs Specialist
Phone: (512) 834-6255
Fax: (512) 834-6313
Email: Teffany_Hutto@encoremed.com

Classification Name: Hip joint metal/metal semi-constrained, with an uncemented component, prosthesis per 21 CFR 888.3330

Description: The modification consists of a change to the Instructions for Use to minimize the necessity for multiple IFU's and to update the contents to reflect current practice.

Intended Use: Joint replacement is indicated for patients suffering from disability due to:

- noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis of the natural femoral head;
- rheumatoid arthritis;
- correction of functional deformity;
- femoral fracture;

This device may also be indicated in the salvage of previously failed surgical attempts.

Comparable Features to Predicate Device(s): Features comparable to predicate devices include the same materials, design, indications, packaging, and sterilization.



APR 4 - 2007

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Encore Medical, L.P.
% Ms. Teffany Hutto
Regulatory Affairs Specialist
9800 Metric Boulevard
Austin, Texas 78758

Re: K070221

Trade/Device Name: FMP™ Metal/Metal Acetabular Insert; Metal/Metal Hip System;
CLP® Offset Total Hip System
Regulation Number: 21 CFR 888.3330
Regulation Name: Hip joint metal/metal semi-constrained, with uncemented acetabular
component, prosthesis
Regulatory Class: Class III
Product Codes: KWA, JDI, KWL, KWY, KWZ, LPH, LWJ, LZO
Dated: January 23, 2007
Received: January 24, 2007

Dear Ms. Hutto:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Mark N. Melkerson", is written over the typed name.

Mark N. Melkerson

Director

Division of General, Restorative
and Neurological Devices

Office of Device Evaluation

Center for Devices and
Radiological Health

Enclosure

510(k) Number (if known): K070221

Device Name: FMP™ Metal/Metal Acetabular Insert

Indications for Use:

FMP™ Metal/Metal Acetabular Insert
Indications for Use

Joint replacement is indicated for patients suffering from disability due to:

- noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis of the natural femoral head;
- rheumatoid arthritis;
- correction of functional deformity;
- femoral fracture;

This device may also be indicated in the salvage of previously failed surgical attempts.

Prescription Use X
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _____
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)


(Division Sign-Off)

**Division of General, Restorative,
and Neurological Devices**

510(k) Number K070221

510(k) Number (if known): K070221

Device Name: Metal/Metal Hip System

Indications for Use:

**Metal/Metal Hip System
Indications for Use**

Joint replacement is indicated for patients suffering from disability due to:

- noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis of the natural femoral head;
- rheumatoid arthritis;
- correction of functional deformity;
- femoral fracture;

This device may also be indicated in the salvage of previously failed surgical attempts.

Prescription Use X
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _____
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

510(k) Number (if known): K070221

Device Name: CLP® Offset Total Hip System

Indications for Use:

**CLP® Offset Total Hip System
Indications for Use**

Joint replacement is indicated for patients suffering from disability due to:

- noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis of the natural femoral head;
- rheumatoid arthritis;
- correction of functional deformity;
- femoral fracture;

This device may also be indicated in the salvage of previously failed surgical attempts.

Prescription Use X
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _____
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)